Restored Cytokine-Producing Capacities of Mucosal-associated Invariant T Cells in Pediatric Cystic Fibrosis Patients Treated with Elexacaftor/Tezacaftor/Ivacaftor
Emmanuelle Bardin(Inserm), Maria Leite‐de‐Moraes(Centre National de la Recherche Scientifique), Anne Jamet(Université Paris Cité), Messaouda Attailia(Urology Team), Céline Dietrich(Urology Team), Isabelle Sermet‐Gaudelus(Hôpital Necker-Enfants Malades), Agnès Ferroni(Hôpital Necker-Enfants Malades), Guillaume Lezmi(Hôpital Necker-Enfants Malades)
Cited by 2
Related Papers
<i>Pseudomonas aeruginosa</i>infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches
|Expert Review of Respiratory Medicine|2016|170
<i>Mycobacterium abscessus</i>and Children with Cystic Fibrosis
|Emerging infectious diseases|2003|159
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy
|New England Journal of Medicine|2023|129
Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis
|FEMS Microbiology Letters|2017|107
A New Family of Secreted Toxins in Pathogenic Neisseria Species
|PLoS Pathogens|2015|77